Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A

Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A

SSSE:605199
5.20
CNY
-0.15
(-2.80%)
-1.01EPS
2.08BMarket Cap

Total Valuation

CNY

As of June 30, 2026, Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A carries a market capitalization of 2.08B, placing it among publicly traded companies globally. Its enterprise value stands at 3.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.08B
Enterprise Value3.13B

Share Statistics

As of June 30, 2026, Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A has 400.11M shares outstanding.

Shares Outstanding400.11M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 3.32, and the price-to-book ratio stands at 6.94.

PS Ratio3.32
PB Ratio6.94
P/TBV Ratio70.79

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 4.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.13B versus a market cap of 2.08B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales4.97

Financial Position

As of June 30, 2026, Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A maintains a current ratio of 0.51, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 303.54, indicating elevated leverage, while an interest coverage ratio of -9.83 demonstrates limited ability to service its debt obligations.

Current Ratio0.51
Quick Ratio0.03
Debt / Equity303.54
Debt / EBITDA-2.78
Interest Coverage-9.83

Financial Efficiency

CNY

Over the twelve months ended June 30, 2026, Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A posted a negative return on equity (ROE) of -80.37, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -15.17, reflecting losses generated across the asset base. The company generates approximately 390,230.18 in revenue per employee across its workforce of 1,614.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.55 indicates how many times Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-80.37
Return on Assets (ROA)-15.17
Revenue Per Employee390,230.18
Employee Count1,614.00
Inventory Turnover1.55

Taxes

CNY

Over the twelve months ended June 30, 2026, Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A recorded 15.46M in income tax expense. The company reported a pretax loss of -393.26M and -411.49M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax15.46M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A's stock has declined approximately 47.79% over the past 52 weeks. The 50-day moving average sits at 5.62, while the 200-day moving average is 6.22.

52-Week Price Change-47.79%
50-Day Moving Average5.62
200-Day Moving Average6.22

Income Statement

CNY

Over the twelve months ended June 30, 2026, Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A generated 629.83M in revenue and converted that into -411.49M in net income, yielding earnings per share of -1.01. EBITDA reached -377.67M, while operating income came in at -263.62M.

Revenue629.83M
Gross Profit115.56M
Operating Income-263.62M
Pretax Income-393.26M
Net Income-411.49M
EBITDA-377.67M
EBIT-377.67M
Earnings Per Share (EPS)-1.01

Balance Sheet

CNY

As of June 30, 2026, Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A holds 38.91M in cash and equivalents against 1.05B in total debt, resulting in a net debt position of 840.38M. Total book value stands at 299.11M, with working capital of -714.34M providing operational flexibility.

Cash & Cash Equivalents38.91M
Total Debt1.05B
Net Debt840.38M
Equity (Book Value)299.11M
Book Value Per Share0.75
Working Capital-714.34M

Cash Flow

CNY

These figures cover the twelve months ended June 30, 2026.

Capital Expenditures-46.09M

Margins

Over the twelve months ended June 30, 2026, Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A posted a gross margin of 18.35, reflecting its pricing power and cost economics. The operating margin of -41.85 and net profit margin of -65.33 provide insight into operational efficiency.

Gross Margin18.35
Operating Margin-41.85
Pretax Margin-62.44
Profit Margin-65.33
EBITDA Margin-59.96

Dividends & Yields

CNY

Over the twelve months ended June 30, 2026, Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A paid dividends of 0.07 per share. The dividend payout ratio of -7.01 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 11.81, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A shareholders.

Dividend Per Share0.07
Payout Ratio-7.01
Shareholder Yield11.81

Scores

As of June 30, 2026, Hainan Huluwa Pharmaceutical Group Co. Ltd. Class A has an Altman Z-Score of -0.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-0.20